The aim of the call is to support pragmatic, phase III, randomised controlled, multi-national interventional Investigator-Initiated Clinical Studies (IICS)(1) that are designed as following study types:comparative-effectiveness studies and/ordrug repurposing studies of off-patent drugsApplicants can make use of existing cohorts, e.g. for designing Trials within Cohorts (TwiCs).(2) that have a high public relevance in the fields of these specific diseases or conditions (that are of equal importance):Cardiovascular diseasesMetabolic disordersAutoimmune diseasesNon-communicable respiratory diseasesThe multi-national Investigator-Initiated Clinical Studies should primarily address at least one of the abovementioned principal diseases/conditions, although the proposals can also address several of the mentioned diseases/conditions and/or in combination with related comorbidities.(3) that ensure inclusivity and diversity in the study population and also include sex/gender-sensitive, age-specific or other diversity-related aspects, if reasonable.Out of Scope· Clinical studies conducted for direct commercial purposes· For drug repurposing studies: a drug still on patent in one of the participating countries. This criterion also applies to biological medicinal products and biosimilars.· Phase I and Phase II studies: Studies in which a treatment is used in humans for the first time, or which are aimed exclusively at assessing tolerability, safety or dose determination· Proposals focused on observational studies, non-interventional cohort studies, implementation studies, translational/clinical approval studies, creation of large databases, systematic reviews and meta-analysis. Non-randomised studies.· Studies in other medical areas which are not mentioned above (cardiovascular diseases, metabolic disorders, autoimmune diseases and non-communicable respiratory diseases). Particularly, those clinical studies that are focused on cancer are out of the scope of this call, even if th